var data={"title":"Blinatumomab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Blinatumomab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/762571?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=blinatumomab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Blinatumomab: Patient drug information&quot;</a> and <a href=\"topic.htm?path=blinatumomab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Blinatumomab: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595546\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cytokine release syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving blinatumomab. Interrupt or discontinue blinatumomab as recommended.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neurotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving blinatumomab. Interrupt or discontinue blinatumomab as recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714123\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Blincyto</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46324316\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Blincyto</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595670\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anti-CD19/CD3;</li>\n      <li>\n        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821526\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Hospitalization is recommended for the first 9 days of cycle 1, and the first 2 days of cycle 2. Close observation by a healthcare professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premedicate with dexamethasone 20 mg one hour prior to the first dose of each cycle, prior to a step dose (eg, Cycle 1 day 8), or when restarting therapy after an interruption of &ge;4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute lymphoblastic leukemia (B-cell precursor), relapsed/refractory:</b> IV: Each induction and consolidation treatment cycle consists of 4 weeks of continuous infusion followed by a 2-week treatment-free interval (allow at least 2 weeks treatment-free between cycles). Each continued therapy cycle consists of 4 weeks of continuous infusion followed by an 8-week treatment-free interval. Therapy involves up to 2 induction cycles followed by 3 additional cycles for consolidation and up to 4 additional cycles of continued therapy (total of up to 9 cycles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &ge;45 kg (fixed dose):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycle 1: 9 <b>mcg</b> daily administered as a continuous infusion on days 1 to 7, followed by 28 <b>mcg</b> daily as a continuous infusion on days 8 to 28 of a 6-week treatment cycle (Kantarjian 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 2 through 5: 28 <b>mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle (Kantarjian 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 6 through 9: 28<b> mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle (Kantarjian 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &lt;45 kg (dose based on BSA):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycle 1: 5 <b>mcg</b>/m<sup>2</sup>/day (maximum: 9 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 7, followed by 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) as a continuous infusion on days 8 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 2 through 5: 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 6 through 9: 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48879146\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=blinatumomab-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Blinatumomab: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Hospitalization is recommended for the first 9 days of cycle 1, and the first 2 days of cycle 2. Close observation by a healthcare professional (or hospitalization) is recommended for initiation of all subsequent cycles or for therapy reinitiation (eg, treatment is interrupted for 4 or more hours). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premedicate with dexamethasone 5 mg/m<sup>2</sup> (maximum: 20 mg) one hour prior to the first dose of the first cycle, prior to a step dose (eg, Cycle 1 day 8), or when restarting therapy after an interruption of &ge;4 hours in the first cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute lymphoblastic leukemia (B-cell precursor), relapsed/refractory: </b>IV: Each induction or consolidation treatment cycle consists of 4 weeks of continuous infusion followed by a 2-week treatment-free interval (allow at least 2 weeks treatment-free between cycles). Each continued therapy cycle consists of 4 weeks of continuous infusion followed by an 8-week treatment-free interval. Therapy involves 2 induction cycles followed by 3 additional cycles for consolidation and up to 4 additional cycles of continued therapy (total of up to 9 cycles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &ge;45 kg (fixed dose):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycle 1: 9 <b>mcg</b> daily administered as a continuous infusion on days 1 to 7, followed by 28 <b>mcg</b> daily as a continuous infusion on days 8 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 2 through 5: 28 <b>mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 6 through 9: 28<b> mcg</b> daily administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &lt;45 kg (dose based on BSA):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycle 1: 5 <b>mcg</b>/m<sup>2</sup>/day (maximum: 9 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 7, followed by 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) as a continuous infusion on days 8 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 2 through 5: 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cycles 6 through 9: 15 <b>mcg</b>/m<sup>2</sup>/day (maximum: 28 <b>mcg</b>/day) administered as a continuous infusion on days 1 to 28 of a 12-week treatment cycle</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821552\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821553\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling; however, a pharmacokinetic analysis showed that clearance values in patients with CrCl 30 to 59 mL/minute were similar to the range observed in patients with normal renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26834631\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatotoxicity during treatment: Interrupt therapy if transaminases are &gt;5 times ULN or if bilirubin is &gt;3 times ULN.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821554\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">If the interruption after an adverse event is no longer than 7 days, continue the same cycle to a total of 28 days of infusion inclusive of days before and after the interruption in that cycle. If an interruption due to an adverse event is longer than 7 days, start a new cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Cytokine release syndrome (CRS):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Interrupt therapy until resolved, then resume dosing at 9 <b>mcg</b> daily (or 5 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg). Increase dose to 28 <b>mcg</b> daily (or 15 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg) after 7 days if toxicity does not recur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Neurologic toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Interrupt therapy for at least 3 days and until toxicity is &le; Grade 1 (mild), then resume dosing at 9 <b>mcg</b> daily (or 5 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg). Increase dose to 28 <b>mcg</b> daily (or 15 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg) after 7 days if toxicity does not recur. If toxicity occurred at the 9 <b>mcg</b> daily dose (or 5 <b>mcg</b>/m<sup>2</sup>/day dose if &lt;45 kg), or if it takes more than 7 days to resolve, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: Discontinue permanently</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Seizure: Discontinue permanently if more than 1 seizure occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Other clinically relevant toxicity:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Interrupt therapy until toxicity is &le; Grade 1 (mild), then resume dosing at 9 <b>mcg</b> daily (or 5 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg). Increase dose to 28 <b>mcg</b> daily (or 15 <b>mcg</b>/m<sup>2</sup>/day if &lt;45 kg) after 7 days if toxicity does not recur. If toxicity takes more than 14 days to resolve, discontinue permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4: Consider discontinuing permanently.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714124\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Blincyto: 35 mcg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26714122\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46437844\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Provided with IV solution stabilizer to coat the prefilled NS bag prior to addition of reconstituted blinatumomab (do NOT use IV solution stabilizer for reconstitution of blinatumomab).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46437845\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution Reconstituted, Intravenous [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blincyto: 38.5 mcg (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26619135\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Blincyto: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf#page=33&amp;token=x2/X4Xv9byVvTK3s5NszrBkZekKqJ7gTI7vP3Ph2HTlDYEXqd9LJBjpAIOvA9LGLnofw3o4u/InzNpYdrkcRb0ZqJT2LSy1pyMnW59L8F3NBpaFzvDb4bi5OyrknRJdj&amp;TOPIC_ID=98582\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125557s008lbl.pdf#page=33</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821576\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Preparation and administration errors have occurred; carefully follow administration instructions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>24- or 48-hour infusion:</i> Administer 240 mL as a continuous IV infusion at a constant flow rate of 10 mL/hour for 24 hours or 5 mL/hour for 48 hours (depending on dose, duration, and/or concentration) through a dedicated lumen. Use a programmable, lockable, non-elastomeric infusion pump with an alarm; IV tubing should include a sterile, nonpyrogenic, low protein-binding, 0.2 micron in-line filter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <i>7-day infusion (<b>not</b> recommended in patients weighing &lt;22 kg): </i>Administer 100 mL as a continuous IV infusion at a constant flow rate of 0.6 mL/hour for 7 days through a dedicated lumen. Use a programmable, lockable, non-elastomeric infusion pump with an alarm; an in-line filter is not required for the 7-day infusion bag.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Only use polyolefin, non-DEHP PVC (non-di-ethylhexylphthalate PVC), or ethyl vinyl acetate (EVA) infusion bags, pump cassettes and IV tubing. IV tubing should be primed with prepared infusion solution, not NS. For adults, premedicate with dexamethasone 20 mg one hour prior to the first dose of each cycle, prior to a step dose (such as cycle 1 day 8), or when restarting therapy after an interruption of &ge;4 hours. For pediatric patients, premedicate with dexamethasone 5 mg/m<sup>2</sup> (maximum: 20 mg) one hour prior to the first dose of the first cycle, prior to a step dose (eg, Cycle 1 day 8), or when restarting therapy after an interruption of &ge;4 hours in the first cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Infusion bag contains overfill (to account for tubing priming volume). Do <b>not</b> flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in excess dosage and complications. Do not infuse other medications through the same line.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595548\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute lymphoblastic leukemia:</b> Treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821363\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:6em;\">Blinatumomab may be confused with bezlotoxumab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Preparation and administration errors have occurred. Do not flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose and complications. IV bag contains overfill and volume will be more than the volume administered to the patient to account for IV line priming and to ensure that the full dose is administered. Carefully follow preparation and administration instructions. Refer to manufacturer labeling for further information.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26931910\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (18%), cardiac arrhythmia (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased absolute lymphocyte count (grades 3 or 4: 80%), neutropenia (31%; &ge; grade 3: 28%), anemia (25%; &ge; grade 3: 19%), thrombocytopenia (21%; &ge; grade 3: 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (15%), increased serum ALT (grades 3/4: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Cytokine release syndrome (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (28%), serious infection (25%), bacterial infection (14%), viral infection (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (&ge;10%; includes essential tremor, intentional tremor, resting tremor)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (55%), infusion related reaction (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (8%; &ge; grade 3: 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum AST (grades 3/4: 8%), increased serum bilirubin (grades 3/4: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (&lt;2%; most were neutralizing)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Capillary leak syndrome, chest discomfort, chest pain, circulatory shock, flushing, hypertension, hypertensive crisis, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Altered mental status, aphasia, ataxia, brain disease, chills, cognitive dysfunction, confusion, cranial nerve dysfunction (facial nerve disorder, facial paresis, trigeminal nerve disorder, trigeminal neuralgia, sixth nerve palsy), depression, disorientation, disturbance in attention, dizziness, drowsiness, equilibrium disturbance, hyperthermia, hypoesthesia, impaired consciousness, insomnia, lethargy, leukoencephalopathy, memory impairment, noncardiac chest pain, pain, seizure (includes atonic seizure), sepsis, speech disturbance, stupor, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Allergic dermatitis, erythema multiforme, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash, hypovolemic shock, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased serum immunoglobulins (including IgA, IgG, IgM), febrile neutropenia, hypogammaglobulinemia, leukocytosis, lymphadenopathy, tumor lysis syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, angioedema, fixed drug eruption, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, limb pain, musculoskeletal chest pain, ostealgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute asthma, bronchospasm, cough, dyspnea, dyspnea on exertion, productive cough, respiratory distress, tachypnea, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595549\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to blinatumomab or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821436\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia and neutropenic fever, including life-threatening episodes, have been reported. Monitor blood counts throughout therapy; may require therapy interruption if prolonged neutropenia occurs. Anemia and thrombocytopenia may also occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytokine release syndrome: <b>[US Boxed Warning]: Cytokine release syndrome (CRS), which may be life-threatening or fatal, has occurred. Interrupt or discontinue therapy as recommended.</b> Infusion reactions have also occurred, and may be difficult to distinguish from CRS. CRS symptoms may include pyrexia, headache, nausea, weakness, hypotension, increased transaminases, and elevated total bilirubin. In some patients, disseminated intravascular coagulation (DIC), capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS) have been reported in the setting of CRS. Monitor closely for signs/symptoms of these conditions; may require therapy interruption or discontinuation. CRS which was life-threatening or fatal occurred rarely. The highest cytokine elevation was observed in the first 2 days following the start of infusion. In 1 study, patients with a high tumor burden (&ge;50% leukemic blasts or &gt;15,000/mm<sup>3</sup> peripheral blood leukemic blast counts), or elevated lactate dehydrogenase were pre-treated with dexamethasone (10 to 24 mg/m2/day for up to 5 days and concluding 3 days prior to initiating blinatumomab) to reduce the incidence of severe CRS (Topp 2015). Tocilizumab may be considered in the management of severe or life-threatening cytokine release syndrome associated with bi-specific T-cell engaging (BiTE) therapy (Lee 2014; Maude 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Transient increases in liver enzymes (associated both with and without CRS) may occur during therapy. In patients with ALL, the median time to enzyme elevation was 3 to 19 days; grade 3 or higher elevations were observed in a small percentage of patients. Monitor ALT, AST, GGT, and total bilirubin at baseline and during treatment. Interrupt therapy if transaminases are &gt;5 times ULN or if bilirubin is &gt;3 times ULN.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infection: Serious infections such as sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-related infections have been reported in approximately one-fourth of patients with ALL in clinical trials (may be life-threatening or fatal). Consider prophylactic antibiotics if appropriate, and monitor closely for signs/symptoms of infection. Treat promptly if infection occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukoencephalopathy: Leukoencephalopathy (as seen on MRI) has been reported, particularly in those patients who received prior treatment with cranial irradiation and antileukemia chemotherapy (eg, high-dose methotrexate, intrathecal cytarabine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: Neurological toxicities, which may be severe, life-threatening, or fatal, have occurred. Interrupt or discontinue therapy as recommended.</b> Neurotoxicity has occurred in almost two-thirds of patients with ALL in clinical trials. The median time to onset was within the first 2 weeks of therapy. Common neurological symptoms include headache and tremor (symptoms may differ in children &lt;2 years, and elderly patients have a higher incidence of neurotoxicity). Grade 3 or higher neurotoxicity (eg, encephalopathy, convulsions, speech disorders, disturbances in consciousness, confusion and disorientation, and coordination and balance disorders) has also been observed; other manifestations have included cranial nerve disorders. Neurotoxicity may be managed with dexamethasone (Topp 2015). Patients are at risk for loss of consciousness due to neurologic events while taking blinatumomab; advise patients to avoid driving, participating in hazardous occupations, or operating heavy or dangerous machinery during treatment. Patients with a history of (or current) clinically relevant CNS pathology were excluded from clinical trials. Monitor patients for signs/symptoms of neurotoxicity; may require therapy interruption or discontinuation. The majority of symptoms resolved after interrupting therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Fatal cases of pancreatitis in patients receiving blinatumomab plus dexamethasone have been reported in the postmarketing setting. Monitor for signs/symptoms of pancreatitis; may require therapy interruption or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Life-threatening or fatal tumor lysis syndrome (TLS) has been observed. Administer measures to prevent TLS (eg, pretreatment nontoxic cytoreduction and hydration during treatment). Monitor for signs/symptoms of TLS (eg, acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia); may require treatment interruption or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concomitant drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to blinatumomab initiation, during treatment, and until immune system recovery following the last cycle of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients experienced an increased rate of neurotoxicity (including cognitive disorder), encephalopathy, confusion, and serious infections as compared to patients &lt;65 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pediatric patients experienced an increased rate of anemia, thrombocytopenia, vomiting, pyrexia, and hypertension as compared to adult patients. While the incidence of neurologic toxicities in patients &lt;2 years of age did not differ from other age groups, the manifestations were different; reported toxicities were agitation, headache, insomnia, somnolence, and irritability.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling. Due to the addition of bacteriostatic saline, the 7-day infusion bags of blinatumomab contain benzyl alcohol and are not recommended for use in patients weighing &lt;22 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Safety issue: Preparation and administration errors have occurred. Do not flush infusion line, particularly when changing infusion bags or at completion of infusion; may result in overdose and complications. IV bag contains overfill and volume will be more than the volume administered to the patient to account for IV line priming and to ensure that the full dose is administered. Follow preparation and administration instructions carefully. Refer to manufacturer labeling for further information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639712\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26639709\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98582&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: Blinatumomab may increase the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821445\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproductions studies have not been conducted. Based on the mechanism of action, blinatumomab may cause fetal harm when administered to a pregnant woman. Newborns exposed in utero may develop B-cell lymphocytopenia; monitor B-lymphocytes prior to administering live virus vaccines. Verify pregnancy status of women of reproductive potential prior to initiating treatment; effective contraception should be used during treatment and for at least 48 hours after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821447\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if blinatumomab is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer during treatment and for at least 48 hours after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821589\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, liver function tests (ALT, AST, GGT, and total bilirubin) at baseline and throughout therapy; monitor for signs/symptoms of cytokine release syndrome, infusion reactions, neurotoxicity, infection, pancreatitis, and tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821503\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blinatumomab is a bispecific T-cell engager (BiTE) which binds to CD19 expressed on B-cells and CD3 expressed on T-cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor complex with CD19 on B-cells (malignant and benign), thus forming a cytolytic synapse between a cytotoxic T-cell and the cancer target B-cell (Topp 2014). Blinatumomab mediates the production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T cells, which result in lysis of CD19-positive cells.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26821505\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Pediatric patients 0 to 17 years: 3.14 &plusmn; 2.97 L/m<sup>2</sup>; Adults: 4.35 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Pediatric patients 0 to 17 years: 2.04 &plusmn; 1.35 hours; Adults: 2.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (negligible amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26844484\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Blincyto Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mcg (1): $4,448.92</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49189360\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Blincyto (AT, AU, CR, CZ, DE, DK, DO, EE, FR, GB, GT, HK, HN, HR, IE, IL, IS, KR, LT, NI, NO, PA, PL, PT, RO, SG, SI, SK, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin<i>. J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blincyto (blinatumomab) [prescribing information]. Thousand Oaks, CA: Amgen Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian H, Stein A, G&ouml;kbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. <i>N Engl J Med</i>. 2017;376(9):836-847. doi: 10.1056/NEJMoa1609783.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/28249141/pubmed\" target=\"_blank\" id=\"28249141\">28249141</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124(2):188-195. doi: 10.1182/blood-2014-05-552729.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/24876563/pubmed\" target=\"_blank\" id=\"24876563\">24876563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. <i>Cancer J</i>. 2014;20(2):119-122. doi: 10.1097/PPO.0000000000000035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/24667956/pubmed\" target=\"_blank\" id=\"24667956\">24667956</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp MS, G&ouml;kbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study [published correction appears in <i>Lancet Oncol</i>. 2015;16(4):e158]. <i>Lancet Oncol</i>. 2015;16(1):57-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/25524800/pubmed\" target=\"_blank\" id=\"25524800\">25524800</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursos acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 2014;32(36):4134-4140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/25385737/pubmed\" target=\"_blank\" id=\"25385737\">25385737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. <i>Blood</i>. 2012;120(26):5185-5187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/23024237/pubmed\" target=\"_blank\" id=\"23024237\">23024237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. <i>J Clin Oncol</i>. 2011;29(18):2493-2498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/21576633/pubmed\" target=\"_blank\" id=\"21576633\">21576633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    von Stackelberg A, Locatelli F, Zugmaier G, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>J Clin Oncol</i>. 2016;34(36):4381-4389.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/blinatumomab-drug-information/abstract-text/27998223/pubmed\" target=\"_blank\" id=\"27998223\">27998223</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98582 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26595546\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F26714123\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F46324316\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26595670\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F26821526\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F48879146\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F26821552\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F26821553\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F26834631\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F26821554\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F26714124\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F26714122\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46437844\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F46437845\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F26619135\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F26821576\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26595548\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26821363\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F26931910\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26595549\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F26821436\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F26639712\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F26639709\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F26821445\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F26821447\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F26821589\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F26821503\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F26821505\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F26844484\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F49189360\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/98582|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=blinatumomab-patient-drug-information\" class=\"drug drug_patient\">Blinatumomab: Patient drug information</a></li><li><a href=\"topic.htm?path=blinatumomab-pediatric-drug-information\" class=\"drug drug_pediatric\">Blinatumomab: Pediatric drug information</a></li></ul></div></div>","javascript":null}